Navigation Links
ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011
Date:7/21/2011

EXTON, Pa., July 21, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2011 are expected to be released on Thursday, July 28, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2011 second quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until August 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... GERMANY (PRWEB) May 26, 2015 ... R. Grace & Co. (NYSE: GRA) announces that ... good manufacturing practice (GMP) certification from EXCiPACT™, an ... of pharmaceutical excipients. , All three ... of pharmaceutical grade excipient silica gels have now ...
(Date:5/26/2015)... und HILDEN, Deutschland, May 26, 2015 /PRNewswire/ ... ®   ermöglicht klinischen ... Erstellung dazugehöriger Berichte; Vorstellung auf den Konferenzen ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... von QIAGEN Clinical Insight ® (QCI™) ...
(Date:5/26/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced ... will provide an update on the progress of Sangamo,s ZFP ... company,s business strategy at 1:30pm ET on Monday, June 1, ... is being held in New York, NY ... may be accessed via a link on the Sangamo BioSciences ...
(Date:5/26/2015)...  Alere Inc. (NYSE: ALR ) (the "Company") announced ... file its Quarterly Report on Form 10-Q for the three ... received a notice from the New York Stock Exchange (the ... NYSE,s continued listing requirements under the timely filing criteria established ... The reason for the delay relates to Company,s ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... members help guide non-profit on path to cure ... Project, a Minnesota,non-profit organization created to expedite the ... attracted two well-known experts to its,Board of Directors: ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), Steven D. ...
... 16 Celator Pharmaceuticals today,announced that John Bennett, ... the BIO Business Forum during the Biotechnology Industry,Organization ... will,provide a corporate overview and an update on ... on Wednesday, June 18,2008 at 3:30 PDT in ...
... NovaVision today announced,the appointment of Rudy Mazzocchi as ... is responsible for leveraging the company,s novel,technology to ... patients with,impaired vision have access to NovaVision(R) Vision ... expertise bringing new medical technologies,and devices to market ...
Cached Biology Technology:Spring Point Project Names New Members to Board of Directors 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 3
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... rates are concentrated in the northern part of the ... according to a report in Cancer Epidemiology, Biomarkers ... for Cancer Research. Ahmedin Jemal, D.V.M., Ph.D., vice ... said the decrease in death rates ranged from about ...
... global cooling and warming over the past few million ... they do today, according to a new study by ... The researchers, who analyzed California gray whale ( Eschrichtius ... 120,000 years, also found evidence to support the idea ...
... Move over, boy bands of Americathere,s a new ... Middle School in San Diego, California, entered The Christopher ... (STEM) program that challenges middle-school students to identify a ... Taking a cue from the popular group the Backstreet ...
Cached Biology News:Southern US states lag in reducing death rates from colorectal cancer 2Gray whales likely survived the Ice Ages by changing their diets 2Gray whales likely survived the Ice Ages by changing their diets 3Gray whales likely survived the Ice Ages by changing their diets 4Gray whales likely survived the Ice Ages by changing their diets 5Middle-school students educate community on proper computer posture 2
Request Info...
... is ideal for both radioactive and nonradioactive ... Provides five pre-mixed nucleotide solutions for ... >10 8 cpm/g control DNA using ... the performance of the system Labels ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: